In last trading session, Spyre Therapeutics Inc (NASDAQ:SYRE) saw 0.42 million shares changing hands with its beta currently measuring 2.97. Company’s recent per share price level of $18.04 trading at $0.01 or 0.06% at ring of the bell on the day assigns it a market valuation of $1.09B. That closing price of SYRE’s stock is at a discount of -165.91% from its 52-week high price of $47.97 and is indicating a premium of 4.43% from its 52-week low price of $17.24. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.68 million shares which gives us an average trading volume of 600.54K if we extend that period to 3-months.
For Spyre Therapeutics Inc (SYRE), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.30. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.84 in the current quarter.
Spyre Therapeutics Inc (NASDAQ:SYRE) trade information
Upright in the green during last session for gaining 0.06%, in the last five days SYRE remained trading in the red while hitting it’s week-highest on Monday, 03/10/25 when the stock touched $18.04 price level, adding 8.61% to its value on the day. Spyre Therapeutics Inc’s shares saw a change of -22.51% in year-to-date performance and have moved -7.44% in past 5-day. Spyre Therapeutics Inc (NASDAQ:SYRE) showed a performance of -22.48% in past 30-days. Number of shares sold short was 10.02 million shares which calculate 16.19 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 50 to the stock, which implies a rise of 63.92% to its current value. Analysts have been projecting 40 as a low price target for the stock while placing it at a high target of 71. It follows that stock’s current price would drop -121.73% in reaching the projected high whereas dropping to the targeted low would mean a loss of -121.73% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 44.65% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -12.04% while estimates for its earnings growth in next 5 years are of -5.20%.
Spyre Therapeutics Inc (NASDAQ:SYRE)’s Major holders
Insiders are in possession of 8.74% of company’s total shares while institution are holding 101.10 percent of that, with stock having share float percentage of 110.79%. Investors also watch the number of corporate investors in a company very closely, which is 101.10% institutions for Spyre Therapeutics Inc that are currently holding shares of the company. FMR LLC is the top institutional holder at SYRE for having 7.51 million shares of worth $176.51 million. And as of 2024-06-30, it was holding 16.568 of the company’s outstanding shares.
The second largest institutional holder is FAIRMOUNT FUNDS MANAGEMENT LLC, which was holding about 4.02 million shares on 2024-06-30. The number of shares represents firm’s hold over 8.8668 of outstanding shares, having a total worth of $94.47 million.
On the other hand, Vanguard Total Stock Market Index Fund and Fidelity Growth Company Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 1.66 shares of worth $29.95 million or 2.76% of the total outstanding shares. The later fund manager was in possession of 1.37 shares on Dec 31, 2024 , making its stake of worth around $24.69 million in the company or a holder of 2.27% of company’s stock.
